Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_d26de4dcbd1f7465c6c22dac43bd8600 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_59c6a921f33fe0adc58c2b6177184515 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0940357635e0ac129c355307e8b3c36e http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_30c79ea6efff966e0f2324215b93d25e |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2217-075 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2227-105 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K2267-0312 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2500-10 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-8509 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A01K67-0276 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-70575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-6896 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5058 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5041 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5008 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-08 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-50 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 |
filingDate |
2002-08-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d12a070ac3a121f04d7c083aed0a8296 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d9130cbecc7b4670f706534807c486f2 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3acb17e2e4cc0da023fa7bbd3f6bc859 |
publicationDate |
2003-02-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-03014328-A2 |
titleOfInvention |
Methods and compounds for disruption of cd40r/cd40l signaling in the treatment of alzheimer's disease |
abstract |
The subject invention provides methods of treating amyloidogenic diseases, comprising the administration of therapeutically effective amounts of a composition comprising a carrier and an agent that interferes with the interaction of CD40L and CD40R to an individual afflicted with a amyloidogenic disease. Also provided are methods and/or assay systems for the identification of compounds or other small molecules capable of disrupting the CD40R/CD40L signaling pathway. |
priorityDate |
1999-06-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |